Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy
NCT02129985 on ClinicalTrials.gov · last registry update 2014-05-02
100 participants. Its estimated completion date, June 2015, has passed with no update to the record. Primary outcome, as filed: time to glycaemic remission. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- xiaolong zhao
- Sponsor type
- Other
- Enrollment
- 100
- Started
- 2014-02
- Primary completion
- 2015-06 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
time to glycaemic remission
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.